---
document_datetime: 2025-12-02 04:55:04
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/quviviq.html
document_name: quviviq.html
version: success
processing_time: 0.1099118
conversion_datetime: 2025-12-27 22:57:31.44132
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Quviviq

[RSS](/en/individual-human-medicine.xml/67558)

##### Authorised

This medicine is authorised for use in the European Union

daridorexant Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Quviviq](#news-on)
- [More information on Quviviq](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Quviviq is a medicine for treating adults with insomnia (difficulty sleeping) that has lasted for at least 3 months and has a considerable impact on how they function during the day.

Quviviq contains the active substance daridorexant.

Expand section

Collapse section

## How is Quviviq used?

The medicine can only be obtained with a prescription. It is available as tablets and the recommended dose is one 50-mg tablet in the evening not more than 30 minutes before going to bed. The dose could be one 25-mg tablet in the evening, if your doctor considers a lower dose as appropriate.

The effect of Quviviq may be delayed if taken with or soon after a meal. Your doctor may prescribe a lower dose if you have liver problems or take certain other medicines. Treatment should be kept as short as possible and reassessed by your doctor within 3 months.

For more information about using Quviviq, see the package leaflet or contact your doctor or pharmacist.

## How does Quviviq work?

The active substance in Quviviq, daridorexant, is a dual orexin receptor antagonist (DORA). It works by blocking the action of orexin, a substance produced by the brain that promotes wakefulness. Quviviq does so by attaching to two types of receptors (targets) for orexin. This means that Quviviq helps people to fall asleep more quickly, to stay asleep for longer and to improve functioning during the day.

## What benefits of Quviviq have been shown in studies?

Quviviq has been shown to be effective at increasing the amount of time adults with insomnia can sleep and improving functioning during the day based on two main studies. In one main study involving 930 patients those given 50 mg Quviviq over 3 months were able to reduce the time they spent awake each night by 29 minutes, on average, compared with a reduction of 11 minutes for those given a placebo (dummy treatment). Also, after 3 months of treatment, patients who took 50 mg Quviviq fell asleep around 35 minutes faster than before treatment, while those taking placebo fell asleep 23 minutes faster.

## What are the risks associated with Quviviq?

The most common side effects with Quviviq (which may affect up to 1 in 10 people) are headache and somnolence (sleepiness). Most side effects are mild or moderate.

Quviviq must not be used in people who are hypersensitive (allergic) to any of the ingredients, in people with narcolepsy (a sleep disorder that causes a person to fall asleep suddenly and unexpectedly), or in people who use 'strong CYP3A4 inhibitors' (a group of medicines).

For the full list of side effects and restrictions of Quviviq, see the package leaflet.

## Why is Quviviq authorised in the EU?

Two main studies showed that Quviviq is effective at increasing the amount of time patients with insomnia can sleep and improving functioning during the day. The side effects are considered manageable. The European Medicines Agency therefore decided that Quviviq's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Quviviq?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Quviviq have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Quviviq are continuously monitored. Suspected side effects reported with Quviviq are carefully evaluated and any necessary action taken to protect patients.

## Other information about Quviviq

Quviviq received a marketing authorisation valid throughout the EU on 29 April 2022.

Quviviq : EPAR - Medicine overview

Reference Number: EMA/127096/2022

English (EN) (104.23 KB - PDF)

**First published:** 03/05/2022

[View](/en/documents/overview/quviviq-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-628)

български (BG) (145.65 KB - PDF)

**First published:**

03/05/2022

[View](/bg/documents/overview/quviviq-epar-medicine-overview_bg.pdf)

español (ES) (130.55 KB - PDF)

**First published:**

03/05/2022

[View](/es/documents/overview/quviviq-epar-medicine-overview_es.pdf)

čeština (CS) (142.29 KB - PDF)

**First published:**

03/05/2022

[View](/cs/documents/overview/quviviq-epar-medicine-overview_cs.pdf)

dansk (DA) (120.02 KB - PDF)

**First published:**

03/05/2022

[View](/da/documents/overview/quviviq-epar-medicine-overview_da.pdf)

Deutsch (DE) (122.83 KB - PDF)

**First published:**

03/05/2022

[View](/de/documents/overview/quviviq-epar-medicine-overview_de.pdf)

eesti keel (ET) (129.96 KB - PDF)

**First published:**

03/05/2022

[View](/et/documents/overview/quviviq-epar-medicine-overview_et.pdf)

ελληνικά (EL) (146.31 KB - PDF)

**First published:**

03/05/2022

[View](/el/documents/overview/quviviq-epar-medicine-overview_el.pdf)

français (FR) (121.04 KB - PDF)

**First published:**

03/05/2022

[View](/fr/documents/overview/quviviq-epar-medicine-overview_fr.pdf)

hrvatski (HR) (142.88 KB - PDF)

**First published:**

03/05/2022

[View](/hr/documents/overview/quviviq-epar-medicine-overview_hr.pdf)

italiano (IT) (119.11 KB - PDF)

**First published:**

03/05/2022

[View](/it/documents/overview/quviviq-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (149.34 KB - PDF)

**First published:**

03/05/2022

[View](/lv/documents/overview/quviviq-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (142.11 KB - PDF)

**First published:**

03/05/2022

[View](/lt/documents/overview/quviviq-epar-medicine-overview_lt.pdf)

magyar (HU) (142.47 KB - PDF)

**First published:**

03/05/2022

[View](/hu/documents/overview/quviviq-epar-medicine-overview_hu.pdf)

Malti (MT) (143.49 KB - PDF)

**First published:**

03/05/2022

[View](/mt/documents/overview/quviviq-epar-medicine-overview_mt.pdf)

Nederlands (NL) (120.52 KB - PDF)

**First published:**

03/05/2022

[View](/nl/documents/overview/quviviq-epar-medicine-overview_nl.pdf)

polski (PL) (145.74 KB - PDF)

**First published:**

03/05/2022

[View](/pl/documents/overview/quviviq-epar-medicine-overview_pl.pdf)

português (PT) (120.83 KB - PDF)

**First published:**

03/05/2022

[View](/pt/documents/overview/quviviq-epar-medicine-overview_pt.pdf)

română (RO) (140.31 KB - PDF)

**First published:**

03/05/2022

[View](/ro/documents/overview/quviviq-epar-medicine-overview_ro.pdf)

slovenčina (SK) (142.21 KB - PDF)

**First published:**

03/05/2022

[View](/sk/documents/overview/quviviq-epar-medicine-overview_sk.pdf)

slovenščina (SL) (168.86 KB - PDF)

**First published:**

03/05/2022

[View](/sl/documents/overview/quviviq-epar-medicine-overview_sl.pdf)

Suomi (FI) (118.29 KB - PDF)

**First published:**

03/05/2022

[View](/fi/documents/overview/quviviq-epar-medicine-overview_fi.pdf)

svenska (SV) (118.89 KB - PDF)

**First published:**

03/05/2022

[View](/sv/documents/overview/quviviq-epar-medicine-overview_sv.pdf)

Quviviq : EPAR - Risk-management-plan summary

English (EN) (178.28 KB - PDF)

**First published:** 03/05/2022

[View](/en/documents/rmp-summary/quviviq-epar-risk-management-plan-summary_en.pdf)

## Product information

Quviviq : EPAR - Product information

English (EN) (255.32 KB - PDF)

**First published:** 03/05/2022

**Last updated:** 30/04/2025

[View](/en/documents/product-information/quviviq-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-773)

български (BG) (603.31 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/bg/documents/product-information/quviviq-epar-product-information_bg.pdf)

español (ES) (589.54 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/es/documents/product-information/quviviq-epar-product-information_es.pdf)

čeština (CS) (587.03 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/cs/documents/product-information/quviviq-epar-product-information_cs.pdf)

dansk (DA) (396.94 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/da/documents/product-information/quviviq-epar-product-information_da.pdf)

Deutsch (DE) (465.53 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/de/documents/product-information/quviviq-epar-product-information_de.pdf)

eesti keel (ET) (586.43 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/et/documents/product-information/quviviq-epar-product-information_et.pdf)

ελληνικά (EL) (737.83 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/el/documents/product-information/quviviq-epar-product-information_el.pdf)

français (FR) (771.12 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/fr/documents/product-information/quviviq-epar-product-information_fr.pdf)

hrvatski (HR) (609.35 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/hr/documents/product-information/quviviq-epar-product-information_hr.pdf)

íslenska (IS) (589.18 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/is/documents/product-information/quviviq-epar-product-information_is.pdf)

italiano (IT) (594.54 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/it/documents/product-information/quviviq-epar-product-information_it.pdf)

latviešu valoda (LV) (551.35 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/lv/documents/product-information/quviviq-epar-product-information_lv.pdf)

lietuvių kalba (LT) (572.64 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/lt/documents/product-information/quviviq-epar-product-information_lt.pdf)

magyar (HU) (595.15 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/hu/documents/product-information/quviviq-epar-product-information_hu.pdf)

Malti (MT) (587.37 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/mt/documents/product-information/quviviq-epar-product-information_mt.pdf)

Nederlands (NL) (398.66 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/nl/documents/product-information/quviviq-epar-product-information_nl.pdf)

norsk (NO) (580.35 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/no/documents/product-information/quviviq-epar-product-information_no.pdf)

polski (PL) (573.46 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/pl/documents/product-information/quviviq-epar-product-information_pl.pdf)

português (PT) (652.71 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/pt/documents/product-information/quviviq-epar-product-information_pt.pdf)

română (RO) (566.05 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/ro/documents/product-information/quviviq-epar-product-information_ro.pdf)

slovenčina (SK) (618.84 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/sk/documents/product-information/quviviq-epar-product-information_sk.pdf)

slovenščina (SL) (686.12 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/sl/documents/product-information/quviviq-epar-product-information_sl.pdf)

Suomi (FI) (571.97 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/fi/documents/product-information/quviviq-epar-product-information_fi.pdf)

svenska (SV) (258.16 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

30/04/2025

[View](/sv/documents/product-information/quviviq-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000263355 28/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Quviviq : EPAR - All authorised presentations

English (EN) (43.5 KB - PDF)

**First published:** 03/05/2022

**Last updated:** 08/06/2022

[View](/en/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-353)

български (BG) (54.79 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/bg/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_bg.pdf)

español (ES) (44.68 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/es/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_es.pdf)

čeština (CS) (44.84 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/cs/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (44.78 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/da/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (45.67 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/de/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.55 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/et/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (64.09 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/el/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_el.pdf)

français (FR) (43.97 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/fr/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (57.36 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/hr/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (74.09 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/is/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_is.pdf)

italiano (IT) (44.35 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/it/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (61.98 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/lv/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (63.3 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/lt/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (54.91 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/hu/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (62.19 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/mt/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.71 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/nl/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (45.78 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/no/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_no.pdf)

polski (PL) (54.67 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/pl/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_pl.pdf)

português (PT) (44.79 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/pt/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_pt.pdf)

română (RO) (59.35 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/ro/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (61.45 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/sk/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (61.1 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/sl/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (44.98 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/fi/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (43.7 KB - PDF)

**First published:**

03/05/2022

**Last updated:**

08/06/2022

[View](/sv/documents/all-authorised-presentations/quviviq-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Quviviq Active substance daridorexant hydrochloride International non-proprietary name (INN) or common name daridorexant Therapeutic area (MeSH) Sleep Initiation and Maintenance Disorders Anatomical therapeutic chemical (ATC) code N05CJ03

### Pharmacotherapeutic group

Psycholeptics

### Therapeutic indication

Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

## Authorisation details

EMA product number EMEA/H/C/005634

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Idorsia Pharmaceuticals Deutschland GmbH

Marie-Curie-Strasse 8

Opinion adopted 24/02/2022 Marketing authorisation issued 29/04/2022 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Quviviq : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (124.53 KB - PDF)

**First published:** 30/04/2025

[View](/en/documents/procedural-steps-after/quviviq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Quviviq : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (180.12 KB - PDF)

**First published:** 08/06/2022

**Last updated:** 30/04/2025

[View](/en/documents/procedural-steps-after/quviviq-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Quviviq-H-C-PSUSA-00010993-202401: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/49924/2025

English (EN) (127.35 KB - PDF)

**First published:** 06/02/2025

[View](/en/documents/scientific-conclusion/quviviq-h-c-psusa-00010993-202401-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

CHMP summary of positive opinion for Quviviq

Adopted

Reference Number: EMA/CHMP/72381/2022

English (EN) (95.72 KB - PDF)

**First published:** 25/02/2022

[View](/en/documents/smop/chmp-summary-positive-opinion-quviviq_en.pdf)

## Initial marketing authorisation documents

Quviviq : EPAR - Public assessment report

Adopted

Reference Number: EMA/187589/2022

English (EN) (3.47 MB - PDF)

**First published:** 03/05/2022

[View](/en/documents/assessment-report/quviviq-epar-public-assessment-report_en.pdf)

#### News on Quviviq

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022) 25/02/2022

#### More information on Quviviq

- [EMEA-002121-PIP03-19-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002121-pip03-19-m02)
- [Retrospective, non-interventional multicenter study on the effect of QUVIVIQ in patients with insomnia disorder with comorbid anxiety and/or depression disorders - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000594)
- [QUVIVIQ® Pregnancy Registry (ID-078A403) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000033)
- [Post-authorization observational study on the use of QUVIVIQ in standard clinical setting for the treatment of Chronic Insomnia in France - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000363)

**This page was last updated on** 30/04/2025

## Share this page

[Back to top](#main-content)